MADISON, Tenn., Sept. 26, 2016 /PRNewswire/ -- A recent case study demonstrates that AminoActiv® (http://aminoactiv.com/) anti-inflammatory pain reliever could be beneficial for people diagnosed with irritable bowel syndrome (IBS). A 53-year-old patient in Ohio endured the disorder for almost 20 years but reports experiencing a near-complete reversal of his symptoms within two weeks. This breakthrough happened shortly after beginning a regimen of AminoActiv® for lower back pain.
It is reported that IBS affects about 45 million Americans, according to the Mayo Clinic. The disorder can cause diarrhea, cramps, abdominal pain, bloating and/or constipation. IBS is chronic, meaning patients can manage symptoms to varying degrees of success, but there is no cure. Symptoms manifest when the muscles lining the intestinal walls contract erratically, or when these contractions are weaker or stronger than normal.
Doctors don't yet know all of the underlying causes of IBS. Food, hormones, stress and other illnesses can all trigger or exacerbate the disorder. The patient in this case study had none of the usual risk factors like a family history of the disorder or any other health issues that could lead to IBS. At first, his symptoms flared up after eating greasy foods or green, leafy foods. Within several years, the disorder had worsened to the point that eating any kind of food caused almost immediate bowel distress.
The patient's major symptoms included thin, watery, oily excretions and a continuous feeling of having "to go" even after just going. This urge would often be sudden and nearly uncontrollable. Alcohol consumption made these symptoms even more severe on following days.
Previous treatment of the patient's IBS followed the usual course, including a range of anti-diarrhea medications, probiotics, yogurt, fiber supplements, antibiotics, herbs, vitamins and dietary changes. None of these treatments offered any noticeable benefits. The patient was not treated with either of the prescription medications Lotronex® or Amitiza®, which have limited efficacy in cases like this.
The subject of this case study began taking AminoActiv® in May 2016 to relieve his chronic lower back pain. He noticed an improvement of his IBS symptoms within 3 days. After increasing the dosage, those symptoms all but disappeared by the 2-week mark. None of the usual triggers – food, alcohol – led to an increase in symptoms. The patient's therapeutic effects have continued for over 4 months, restoring a quality of life that had been lost.
AminoActiv® is a holistic and non-toxic anti-inflammatory product developed by Vireo Systems as an alternative to NSAID pain relievers, which all have harmful side effects. For more information about the company's entire product line, visit https://vireosystems.com/.
NOTE: This case study is neither an endorsement of any product nor connected to any FDA-approved clinical studies. Toxicity studies (submitted to the FDA) involving the main active ingredient of AminoActiv® indicate the product is safe and has no known contraindications or drug-drug interactions.
About Vireo Systems, Inc.
Taking its name from one of the Latin words for "health," Vireo Systems, Inc. is the manufacturer of a number of nutraceuticals and health products including AminoActiv, the #1 alternative to ibuprofen and NSAIDs. The company was founded in 2002 as part of a project with several university-based researchers, and today, the company's products deliver safe, effective relief for inflammation and pain as well as other health conditions. Vireo Systems, Inc. manufactures CanineActiv and other health-related products in a GMP and HACCP compliant facility. Its manufacturing facility also is SQF product safety management certified.
Vireo Systems, Inc. is headquartered just outside Nashville, Tenn., with a major manufacturing facility in Plattsmouth, Neb.
Product Manager, Vireo Systems, Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aminoactiv-delivers-unexpected-relief-of-ohio-mans-ibs-symptoms-300333983.html
SOURCE Vireo Systems, Inc.